Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants

Kang Wang, Zijing Jia, Linilin Bao, Lei Wang, Lei Cao, Hang Chi, Yaling Hu, Qianqian Li, Yunjiao Zhou, Yinan Jiang, Qianhui Zhu, Yongqiang Deng, Pan Liu, Nan Wang, Lin Wang, Min Liu, Yurong Li, Boling Zhu, Kaiyue Fan, Wangjun Fu, Peng Yang, Xinran Pei, Zhen Cui, Lili Qin, Pingju Ge, Jiajing Wu, Shuo Liu, Yiding Chen, Weijin Huang, Qiao Wang (), Cheng-Feng Qin (), Youchun Wang (), Chuan Qin () and Xiangxi Wang ()
Additional contact information
Kang Wang: Chinese Academy of Sciences
Zijing Jia: Chinese Academy of Sciences
Linilin Bao: Peking Union Medical College
Lei Wang: Chinese Academy of Sciences
Lei Cao: Chinese Academy of Sciences
Hang Chi: Beijing Institute of Microbiology and Epidemiology AMMS
Yaling Hu: Sinovac Biotech
Qianqian Li: National Institutes for Food and Drug Control (NIFDC)
Yunjiao Zhou: Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University
Yinan Jiang: Acrobiosystems
Qianhui Zhu: Chinese Academy of Sciences
Yongqiang Deng: Beijing Institute of Microbiology and Epidemiology AMMS
Pan Liu: Chinese Academy of Sciences
Nan Wang: Chinese Academy of Sciences
Lin Wang: Sinovac Biotech
Min Liu: Sinovac Biotech
Yurong Li: Sinovac Biotech
Boling Zhu: Chinese Academy of Sciences
Kaiyue Fan: Chinese Academy of Sciences
Wangjun Fu: Chinese Academy of Sciences
Peng Yang: Chinese Academy of Sciences
Xinran Pei: Chinese Academy of Sciences
Zhen Cui: Chinese Academy of Sciences
Lili Qin: Acrobiosystems
Pingju Ge: Acrobiosystems
Jiajing Wu: National Institutes for Food and Drug Control (NIFDC)
Shuo Liu: National Institutes for Food and Drug Control (NIFDC)
Yiding Chen: Acrobiosystems
Weijin Huang: National Institutes for Food and Drug Control (NIFDC)
Qiao Wang: Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University
Cheng-Feng Qin: Beijing Institute of Microbiology and Epidemiology AMMS
Youchun Wang: National Institutes for Food and Drug Control (NIFDC)
Chuan Qin: Peking Union Medical College
Xiangxi Wang: Chinese Academy of Sciences

Nature, 2022, vol. 603, issue 7903, 919-925

Abstract: Abstract Omicron (B.1.1.529), the most heavily mutated SARS-CoV-2 variant so far, is highly resistant to neutralizing antibodies, raising concerns about the effectiveness of antibody therapies and vaccines1,2. Here we examined whether sera from individuals who received two or three doses of inactivated SARS-CoV-2 vaccine could neutralize authentic Omicron. The seroconversion rates of neutralizing antibodies were 3.3% (2 out of 60) and 95% (57 out of 60) for individuals who had received 2 and 3 doses of vaccine, respectively. For recipients of three vaccine doses, the geometric mean neutralization antibody titre for Omicron was 16.5-fold lower than for the ancestral virus (254). We isolated 323 human monoclonal antibodies derived from memory B cells in triple vaccinees, half of which recognized the receptor-binding domain, and showed that a subset (24 out of 163) potently neutralized all SARS-CoV-2 variants of concern, including Omicron. Therapeutic treatments with representative broadly neutralizing monoclonal antibodies were highly protective against infection of mice with SARS-CoV-2 Beta (B.1.351) and Omicron. Atomic structures of the Omicron spike protein in complex with three classes of antibodies that were active against all five variants of concern defined the binding and neutralizing determinants and revealed a key antibody escape site, G446S, that confers greater resistance to a class of antibodies that bind on the right shoulder of the receptor-binding domain by altering local conformation at the binding interface. Our results rationalize the use of three-dose immunization regimens and suggest that the fundamental epitopes revealed by these broadly ultrapotent antibodies are rational targets for a universal sarbecovirus vaccine.

Date: 2022
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41586-022-04466-x Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:603:y:2022:i:7903:d:10.1038_s41586-022-04466-x

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-022-04466-x

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().